ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
35 announcements
Wockhardt's monitoring agency report confirms no deviation in QIP proceeds use for the quarter ended September 30, 2026. It is routine periodic compliance with no financial event.
Wockhardt designated Mr. Sumit Garg as Chief Digital & Information Officer, a Senior Management Personnel, from 02 November 2026. He brings over 30 years of technology and transformation leadership experience.
Wockhardt reported Q2 FY27 PAT of Rs.73 Cr on revenue of Rs.969 Cr, up 24%. Biotech operations grew 68%, driven by emerging markets.
Wockhardt Ltd reported revenue from operations of ₹969 Cr (+23.9% YoY) and net profit of ₹73 Cr (-11.0% YoY) for Q2 FY27.
Wockhardt allotted 20,000 equity shares at Rs.5 exercise price under its ESOS 2011 scheme. Paid-up capital increases to 16,25,12,169 shares of Rs.5 each.
Wockhardt Ltd intimated that its Board will meet on 2 Nov 2026 to approve Q1 FY27 unaudited results. The trading window remains closed until 48 hours post-declaration.
The company submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31.
Wockhardt Limited received an order from the Commissioner of Customs imposing a ₹5 Crore penalty and ₹10 Crore redemption fine. The company plans to challenge this order.
Wockhardt Limited received an adjudication order from the Commissioner of Customs imposing penalties and redemption fines aggregating to ₹16 Crore regarding API mis-classification.
Wockhardt Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms no deviation in the utilization of QIP proceeds.
Wockhardt Limited launched the 'Wockhardt Antibiotic Academy,' an open scientific learning platform aimed at facilitating knowledge exchange to tackle multidrug resistance among healthcare professionals.
Wockhardt Ltd reported revenue from operations of ₹929 Cr (+25.9% YoY) and net profit of ₹107 Cr for Q1 FY27.
Wockhardt Limited issued an AGM notice for August 10, 2026. The agenda includes approval for raising up to ₹3,000 Crore via QIP.
Wockhardt Limited issued an addendum to its 27th AGM notice, revising the meeting time to 10:30 a.m. and adding disclosures regarding Related Party Transactions.
Wockhardt Limited has scheduled a board meeting for August 10, 2026, to consider and approve its standalone and consolidated unaudited financial results for the quarter.
Wockhardt Ltd submitted its quarterly shareholding pattern disclosure for the period ended June 30, 2026, in compliance with SEBI Regulation 31(1)(b).
Wockhardt Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The document details holdings across promoter and public categories.
Wockhardt Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report includes an independent assurance statement on BRSR Core parameters.
Wockhardt Limited convened its AGM for August 10, 2026. Key agenda items include a Rs. 3,000 Crore fund raise and approval for material related party transactions.
Wockhardt Limited convened its 27th AGM for August 10, 2026. Agenda items include a proposed Rs. 3,000 Crore fund raise and material related party transactions.
Wockhardt reports FY26 revenue of ₹3,373cr with 51% EBITDA growth. Strategy focuses on novel antibiotic 'Zaynich', recently US FDA approved, and diabetes biosimilars to drive future scaling.
Wockhardt FY26 revenue reached INR 3,373 Cr with EBITDA of INR 630 Cr (18.6% margin). Strategy focuses on Novel Antibiotics (Zaynich) and Biosimilars.
Wockhardt Limited submitted its Annual Secretarial Compliance Report for FY2026. The report notes minor delays in GST and subsidiary disclosures, resulting in regulatory penalties.
Wockhardt received CDSCO marketing authorization for its breakthrough antibiotic, ZAYNICH, in India. The drug targets complicated urinary tract infections, addressing significant unmet medical needs in antibiotic resistance.
ICRA upgraded Wockhardt Limited's long-term credit rating to A- (Stable). The upgrade reflects improved financial performance and healthy market positioning.
Wockhardt Limited announced three senior management appointments. Mr. Om Narayan and Mr. Sunil Soni join as Senior Vice Presidents in Biotech Research and Biotechnology, respectively. Ms. Annapurna Das, formerly of Takeda India, is appointed President for India Business & Emerging Markets (NCE). These leadership additions bring extensive pharmaceutical and biotech expertise to the company.
Wockhardt Limited filed its quarterly Monitoring Agency Report for the QIP proceeds. As of March 31, 2026, the company utilized ₹815.46 Crore out of ₹977.79 Crore net proceeds. The Board extended the utilization timeline for the remaining ₹162.33 Crore, earmarked for R&D and capital expenditure, until financial year 2028.
Wockhardt Limited has designated Ms. Annapurna Das, Mr. Om Narayan, and Mr. Sunil Soni as Senior Management Personnel effective May 4, 2026. These appointments strengthen the company's leadership in India business, emerging markets, biotech research, and biotechnology operations.
Wockhardt Limited reported a positive Profit Before Tax (PBT) of ₹238 Crore for FY26 on total revenue of ₹3,373 Crore. Q4FY26 revenue grew 30% to ₹965 Crore, driven by biotech and antibiotic segments. The company successfully completed Phase 3 trials for five novel antibiotics and holds 859 patents.
Wockhardt Ltd reported revenue from operations of ₹965 Cr (+29.9% YoY) and net profit of ₹164 Cr for Q4 FY26.